SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Short Interest Up 142.0% in February
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY - Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 235,641 shares, a growth of 142.0% from the February 12th total of 97,374 shares. Approximately 1.1% of the company's shares are short sold.
RLY: Tactical ETF Focusing On Natural Resources And Infrastructure
The State Street SPDR SSGA Multi-Asset Real Return ETF targets real returns above inflation via active allocation across inflation-linked assets, real estate, commodities, and infrastructure. RLY's portfolio is currently heavily weighted in equities related to natural resources and infrastructure, offering strong value characteristics. RLY has reached its objective to outperform inflation in total return since 2012 but has lagged 60/40 and permanent portfolios.
Relay Therapeutics Is A Buy For Its Superb Safety Data
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rates and significantly lower toxicity compared to existing therapies like alpelisib and inavolisib. The Eli Lilly acquisition of STX-478 from Scorpion Therapeutics highlights the value of allosteric PI3Kα inhibitors, positioning RLAY as undervalued and ahead in clinical development.
Relay Therapeutics: A Precision Oncology Play Worth The Risk
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials.
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion opportunities of the RLY-2608 program includes two triplet regimens targeting 1st-line PI3Ka-mutant HR+/HER2- breast cancer patients and phase 1 study for tumors with vascular formations starting in Q1 2025.
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company's RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials and a commercialization partner to unlock broader market potential.
RLY: A Nice Allocation Fund
Asset allocation is still important despite recent performance trends. SPDR® SSgA Multi-Asset Real Return ETF offers a mix of asset class exposure for real returns. The RLY ETF focuses on inflation-protected securities, real estate securities, commodities, and infrastructure companies.
